BIvideocpd2

Name:

Surname:

MP Number:

Email address:

Contact number:

Question 1
In the RE-LY® study, how did dabigatran compare to warfarin with regards to the risk of intracranial haemorrhage?

a) Reduced the risk

b) Increased the risk

c) Similar risk

d) Not compared

Question 2
Which of the following bleeding risks were increased with dabigatran 150 mg but not 100 mg when compared to warfarin in the RE-LY® study?

a) Major bleeding

b) Gastrointestinal haemorrhage

c) Intracranial haemorrhage

d) Life-threatening bleeding

Question 3
How did the risk of life-threatening bleeding with dabigatran compare to that of warfarin in the RE-LY® study?

a) Risk was increased

b) Risk was similar

c) Risk was not compared

d) Risk was decreased

Question 4
What is the reduction in the risk of stroke/systemic embolism for dabigatran compared to warfarin?

a) 72 %

b) 15 %

c) 26 %

d) 14 %

Question 5
Which NOAC is associated with a reduced risk of intracranial haemorrhage when compared to warfarin?

a) Apixaban

b) Dabigatran

c) Rivaroxaban

d) All of the above

Question 6
What was the reduction in the risk of total mortality for dabigatran when compared to warfarin?

a) 14 %

b) 72 %

c) 15 %

d) 26 %

Question 7
What was the duration of follow-up of the RELY-ABLE® study, which assessed the long-term safety of dabigatran?

a) 2 years

b) 4 years

c) ≥ 6 years

d) 10 years

Question 8
What did the RELY-ABLE® study reveal about the long-term safety of dabigatran in AF patients?

a) No new safety signals

b) Incidence of major bleeding remained constant over time

c) Incidence of stroke/systemic embolism remained constant over time

d) All of the above

Question 9
How does dabigatran compare to warfarin for stoke prevention in patients with AF?

a) Less major bleeding with 110 mg dose

b) Better efficacy with 150 mg dose

c) Less intracranial haemorrhage with both doses

d) All of the above

Question 10
Which statement is incorrect?

a) RE-LY® study was not sufficiently powered to evaluate both 110 mg and 150 mg doses of dabigatran

b) Dabigatran has a favourable efficacy and safety profile versus warfarin for stroke prevention in AF

c) RE-LY® was a global, randomized study

d) Dabigatran has a favourable long-term safety profile